Share Email Print

Proceedings Paper

Tri-wave laser therapy for spinal cord injury, neuropathic pain management, and restoration of motor function
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

A laser therapy device using three combined wavelengths 532nm, 808nm, and 1064nm has been demonstrated in clinical studies. Primarily, therapeutic lasers have used wavelengths in the ranges of 632nm through 1064nm, where the optical density (OD) < 5, to achieve pain relief and tissue regeneration. Conventional wisdom would argue against using wavelengths in the region of 532nm, due to poor penetration (OD ~ 8); however, the author’s observations are to the contrary. The 532nm light is efficiently absorbed by chromophores such as oxyhemoglobin, deoxyhemoglobin, and cytochrome c oxidase thereby providing energy to accelerate the healing process. The 808nm light is known to result in Nitric Oxide production thereby reducing inflammation and oxidative stress. All three laser wavelengths likely contribute to pain relief by inhibiting nerve conduction; however, the 1064nm has the deepest penetration. Through the use of this device on over 1000 patients with a variety of acute and chronic neuro-musculoskeletal disorders, the author observed that a majority of these individuals experienced rapid relief from their presenting conditions and most patients reported a tingling sensation upon irradiation. Patient testimonials and thermal images have been collected to document the results of the laser therapy. These studies demonstrate the ability of laser therapy to rapidly alleviate pain from both acute and chronic conditions.

Paper Details

Date Published: 5 March 2015
PDF: 10 pages
Proc. SPIE 9309, Mechanisms for Low-Light Therapy X, 93090G (5 March 2015); doi: 10.1117/12.2076925
Show Author Affiliations
Mark D. Chariff, Therapeutic Laser Applications, LLC (United States)
Peter Olszak, GO Advanced Laser Systems (United States)

Published in SPIE Proceedings Vol. 9309:
Mechanisms for Low-Light Therapy X
Michael R. Hamblin; James D. Carroll; Praveen Arany, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?